Ataxin-2 promotes apoptosis of human neuroblastoma cells

被引:51
作者
Wiedemeyer, R
Westermann, F
Wittke, I
Nowock, J
Schwab, M
机构
[1] German Canc Res Ctr, Dept Cytogenet, D-69121 Heidelberg, Germany
[2] Univ Frankfurt, Sect Mol Neurogenet, D-60590 Frankfurt, Germany
关键词
neuroblastoma; ataxin-2; apoptosis; MYCN; amplification; SCA2;
D O I
10.1038/sj.onc.1206150
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neuroblastoma is a highly heterogeneous tumor of young children. Although many advances have been made towards understanding the molecular mechanisms dictating the phenotypic heterogeneity, the prognosis of children with neuroblastoma, particularly of progressively growing variants, has remained dire. About 10% of neuroblastomas regress spontaneously, probably by apoptosis, while another 20% have amplified the MYCN gene resulting in a poor prognosis. In pursuit of identifying cell death-associated genes in neuroblastoma, we encountered the SCA2 gene, coding for ataxin-2, as an important player. Here, we report that enforced expression of wild-type ataxin-2, but not of mutant ataxin-2, sensitizes neuroblastoma cells for apoptosis. In line with this, higher levels of ataxin-2 were detected in apoptotic cells compared to nonapoptotic cells. Neuroblastoma tumors with amplified MYCN contain significantly less ataxin-2 protein than tumors without amplified MYCN. Collectively, our data suggest that ataxin-2 has an important role in regulating the susceptibility of neuroblastoma cells to apoptotic stimuli in vitro and in vivo.
引用
收藏
页码:401 / 411
页数:11
相关论文
共 40 条
  • [1] Annicchiarico-Petruzzelli M, 2001, MED PEDIATR ONCOL, V36, P115
  • [2] Induction of apoptosis by IFNγ in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit
    Bernassola, F
    Scheuerpflug, C
    Herr, I
    Krammer, PH
    Debatin, KM
    Melino, G
    [J]. CELL DEATH AND DIFFERENTIATION, 1999, 6 (07) : 652 - 660
  • [3] THE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF CHILDREN WITH NEUROBLASTOMA STAGE-IV - THE GPO (GERMAN-PEDIATRIC-ONCOLOGY-SOCIETY) EXPERIENCE
    BERTHOLD, F
    BURDACH, S
    KREMENS, B
    LAMPERT, F
    NIETHAMMER, D
    RIEHM, H
    RITTER, J
    TREUNER, J
    UTSCH, S
    ZIESCHANG, J
    [J]. KLINISCHE PADIATRIE, 1990, 202 (04): : 262 - 269
  • [4] Neuroblastoma - Current drug therapy recommendations as part of the total treatment approach
    Berthold, F
    Hero, B
    [J]. DRUGS, 2000, 59 (06) : 1261 - 1277
  • [5] Cellular responses to interferon-gamma
    Boehm, U
    Klamp, T
    Groot, M
    Howard, JC
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 : 749 - 795
  • [6] N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis
    Boon, K
    Caron, HN
    van Asperen, R
    Valentijn, L
    Hermus, MC
    van Sluis, P
    Roobeek, I
    Weis, I
    Voûte, PA
    Schwab, M
    Versteeg, R
    [J]. EMBO JOURNAL, 2001, 20 (06) : 1383 - 1393
  • [7] The potential tumour suppressor role for caspase-9 (CASP9) in the childhood malignancy, neuroblastoma
    Catchpoole, DR
    Lock, RB
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (17) : 2217 - 2221
  • [8] DAP-kinase is a Ca2+ calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity
    Cohen, O
    Feinstein, E
    Kimchi, A
    [J]. EMBO JOURNAL, 1997, 16 (05) : 998 - 1008
  • [9] De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO
  • [10] 2-4